← 返回

癌症免疫治疗中的 RNA 修饰:免疫细胞和免疫检查点的调节因子

英文原题:RNA modifications in cancer immune therapy: regulators of immune cells and immune checkpoints.

查看英文原题

RNA modifications in cancer immune therapy: regulators of immune cells and immune checkpoints.

PubMed 2024/09/20(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

RNA修饰是改变RNA分子结构和功能的表观遗传变化,在癌症的发生、进展和治疗中发挥着至关重要的作用。免疫检查点抑制剂(ICI)疗法,尤其是PD-1阻断和抗CTLA-4治疗,已经改变了多种癌症的治疗格局,在不同癌症患者的治疗中展现出巨大潜力,但对这些疗法的敏感性仅限于某些个体。本综述全面调查了四种主要RNA修饰的功能和治疗意义,特别强调了m6A在肿瘤免疫细胞和免疫治疗领域的重要性。本综述首先对RNA修饰在免疫细胞群体中所扮演的角色进行了基础性总结,重点关注T细胞、NK细胞、巨噬细胞和树突状细胞。随后我们讨论了RNA修饰如何影响调控免疫检查点表达的复杂机制、ICI疗效的调节以及ICI治疗结局的预测,并综述了靶向RNA修饰所调控基因的药物疗法。最后,我们探讨了RNA修饰在基因编辑、癌症疫苗和过继性T细胞疗法中的作用,为RNA修饰在癌症免疫治疗中的应用提供了有价值的见解。

展开英文摘要原文

RNA modifications are epigenetic changes that alter the structure and function of RNA molecules, playing a crucial role in the onset, progression, and treatment of cancer. Immune checkpoint inhibitor (ICI) therapies, particularly PD-1 blockade and anti-CTLA-4 treatments, have changed the treatment landscape of virous cancers, showing great potential in the treatment of different cancer patients, but sensitivity to these therapies is limited to certain individuals.

This review offers a comprehensive survey of the functions and therapeutic implications of the four principal RNA modifications, particularly highlighting the significance of m6A in the realms of immune cells in tumor and immunotherapy. This review starts by providing a foundational summary of the roles RNA modifications assume within the immune cell community, focusing on T cells, NK cells, macrophages, and dendritic cells.

We then discuss how RNA modifications influence the intricate regulatory mechanisms governing immune checkpoint expression, modulation of ICI efficacy, and prediction of ICI treatment outcomes, and review drug therapies targeting genes regulated by RNA modifications.

Finally, we explore the role of RNA modifications in gene editing, cancer vaccines, and adoptive T cell therapies, offering valuable insights into the use of RNA modifications in cancer immunotherapy.

论文信息

作者
Qin X、Liu H、Zhang Q、Che Y、Lei T、Tang F、Hu Q
单位
Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.China
文献类型
综述
期刊
Frontiers in immunology2024
原文标识
PubMed 39372415 · DOI 10.3389/fimmu.2024.1463847